Form 4: Charles River Labs Director Acquires Shares

George Llado Sr., a Director at Charles River Laboratories, reported the acquisition of 1,438 common shares and 450 restricted stock units.

Summary

• George Llado Sr., a Director at Charles River Laboratories International, Inc., has reported transactions involving company stock.
• On May 8, 2026, Llado acquired 1,438 shares of common stock at a price of $177.62 per share.
• Additionally, on the same date, Llado acquired 450 restricted stock units (RSUs) as a substitute for director service fees.
• The RSUs acquired in the second transaction will vest on the earlier of May 8, 2027, or the business day before the company's next annual shareholder meeting.
• The first batch of 1,438 shares are also unvested restricted stock units vesting on the same schedule.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents routine insider stock acquisition and equity compensation, with no immediate negative or overwhelmingly positive financial news.

Positives

• Director George Llado Sr. has increased his beneficial ownership in Charles River Laboratories through the acquisition of common stock and restricted stock units.
• The acquisition of shares at $177.62 per share indicates a belief in the company's valuation by a key insider.
• The grant of RSUs in lieu of director fees suggests a strategy to align management and director incentives with long-term company performance.

Future Outlook

The restricted stock units are set to vest on May 8, 2027, or the business day prior to the company's next annual meeting of shareholders, indicating a medium-term outlook for these equity awards.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are common in the life sciences and contract research organization (CRO) sector as a means of aligning executive and director compensation with shareholder interests and signaling confidence in the company's prospects.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively, signaling confidence in the company's future performance. The vesting of RSUs aligns director incentives with long-term shareholder value.

Next Steps

• Vesting of restricted stock units on May 8, 2027, or the business day prior to the company's next annual meeting of shareholders.

Key Dates

Keywords

Charles River Laboratories, Form 4, Insider Transaction, Director, Restricted Stock Units, Common Stock, Beneficial Ownership, SEC Filing